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IMPROVEMENT OF ASTHMA CONTROL AND INFLAMMATION IN PEDIATRIC PATIENTS 
UNDERGOING ADENOTONSILLECTOMY.  Jonathan C Levin, Lisa Gagnon, David E Karas, and Geoffrey 
L Chupp.  Section of Pulmonary and Critical Care, Department of Internal Medicine, Yale University 
School of Medicine, New Haven, CT. 
Observational studies have suggested improvement in asthma control after adenotonsillectomy, but 
longitudinal studies that correlate the effect of the procedure on markers of airway inflammation 
with changes in asthma control are limited.  We conducted a longitudinal, observational study on 130 
pediatric patients undergoing adenotonsillectomy, including 66 with asthma and 64 control subjects.  
Asthma Control Test (ACT) scores, chitotriosidase (CHIT1) activity, and YKL-40 (CHI3L1) levels in the 
circulation were measured at the time of surgery and at a 6-month follow-up visit, and genotypes of 
chitinase family proteins were measured at baseline.  Gene expression data was analyzed from blood, 
tonsil, and nasal epithelial tissue samples at baseline and in the blood at follow-up by microarray 
analysis.  Mean ACT scores improved by 3 points (p< 0.001) after 6 months.  85% of children with 
poorly-controlled asthma demonstrated an increase in ACT score of at least 3 points or a decrease in 
Emergency Department/Urgent Care visits, oral corticosteroid courses, or rescue short acting 
bronchodilator usage.  Serum chitinase activity decreased significantly in children with asthma (p< 
0.01), but not in children without asthma (p= 0.83) undergoing tonsillectomy.  Higher chitinase 
activity levels at baseline were associated with improved asthma control following surgery in all 
children with asthma (p< 0.01) and in the subgroup of children with poorly-controlled asthma (p< 
0.05).  Subjects with asthma had a higher allele frequency of the CHIT1 mutation (p< 0.02).  Gene 
expression analysis identified a number of inflammatory genes differentially expressed in children 
who had improved asthma control that were not changed in children without improved control and 
control subjects.  Of particular interest was SerpinB2, a plasmin activation inhibitor previously 
implicated in asthma, significantly downregulated after surgery compared to baseline in children 
with improved control.  This data suggests that adenotonsillectomy improves asthma control by 
modulation of airway inflammation.  Elevated serum chitinase activity may be a clinically useful 
determinant to identify patients with poorly-controlled asthma that will benefit from the procedure. 
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Introduction 
Asthma is an inflammatory disease of the lower airways that remains a significant 
healthcare concern for the pediatric population despite public health and pharmacologic 
advances to control the disease. (1, 2)  Studies have demonstrated a systemic component to 
asthmatic disease, and that the upper airway inflammation may be specifically involved in 
the pathogenesis of asthma. (3-5)  Upper airway infections and inflammation are common 
in the pediatric population; likewise, respiratory infection and allergen exposure are 
frequently indicated as triggers for asthma exacerbations in this population.   
Adenotonsillectomy is one of the most common surgical procedures in children, 
performed to address upper airway lymphoid hypertrophy, infection, and inflammation. (6)  
Its clinical effect on asthma control has been debated, with observational studies 
demonstrating a significant improvement in symptoms, lower healthcare utilization, and 
reduction in controller or rescue medication usage following adenotonsillectomy. (7-10)  
Although there are clear effects of adenotonsillectomy on the upper airway, to our 
knowledge the effect of this procedure has not yet been studied on any markers of airway 
inflammation.   
Pediatric Asthma – Clinical Features and Pathophysiology 
Asthma is the most common chronic disease of childhood; data from the 2009 
National Health Statistics Reports showed that 9.6% of children 0-17 years of age (a total of 
7.1 million) had asthma.  4.0 million children had at least one attack in 2009 and were at 
risk for adverse outcomes such as Emergency Department visits or hospitalizations.  
Asthma prevalence increased from 2001 to 2009. (1)  Pediatric asthma has a significant 
burden; in 2003, there were 12.8 million reported days of missed school due to childhood 
asthma.  In 2004, there were 198,000 total hospitalizations (3% of all pediatric admissions) 
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and 750,000 visits to the emergency room (2.8% of pediatric visits) attributed to childhood 
asthma; mortality rate was 2.5 per 1 million. (2) 
Asthma is characterized by intermittent attacks that include symptoms of cough, 
wheezing, and difficulty breathing.  Attacks can be triggered by respiratory infections, 
allergen exposure (e.g. dust mites, cockroach allergens, animal dander, and molds), 
exposure to irritants (e.g. tobacco smoke), changes in weather, or exercise.  Inflammation 
results in hyperresponsive airways and causes bronchoconstriction and obstruction of 
airflow.  By definition, these symptoms are at least partially reversible.  Obstructive changes 
in airway physiology cause reductions in Forced Expiratory Volume (FEV1) > Forced Vital 
Capacity (FVC) and a low FEV1/FVC ratio.  In children, low FEV1 and FVC, along with a low 
Forced Expiratory Flow (FEF) 25%-75%, are better predictors of disease than FEV1/FVC 
ratio. (11)   
Asthmatic inflammation is mediated by a variety of cell types including Th2 
lymphocytes, eosinohpils, and mast cells.  Th2 cytokines including IL-4, IL-5, and IL-13 
produce inflammation that causes the pathophysiologic changes seen in asthma including 
narrowing of the airways, mucus hypersecretion, and airway hyperresponsiveness.  IgE 
plays a pivotal role in this process as well.  Airway remodeling occurs due to chronic 
inflammation and leads to bronchial smooth muscle hypertrophy, mucous gland 
hyperplasia, thickening of the subepithelial basemsent membrane due to collagen 
deposition, and fibrotic changes. (12)  
A Disease Beyond the Lower Airway 
There is evidence that asthmatic disease exists beyond the lower airways. (3)  
Upper airway respiratory infection and allergen exposure are frequently invoked as triggers 
for exacerbations.  Rhinovirus infection in the nasal airway has been shown to significantly 
increase airway reactivity to both histamine and ragweed antigen, and predisposed patients 
  Levin et. al, 3   
to late asthmatic reactions to the challenge. (4)  Another study showed that over 70% of 
patients with asthma also have rhinitis, and this link has led to the “one airway hypothesis”, 
defining asthma and rhinitis as two manifestations of one inflammatory process. (13)  In 
patients with rhinitis, provocation with a nasal allergen produces eosinophilic inflammation 
in both the upper and lower airways, and provocation of the lower airway with an allergen 
likewise produces in eosinophilic inflammation in both the upper and lower airways. (5)  
Airway and nasal epithelial cells in both disease entities undergo similar structural and 
inflammatory changes; likewise, corticosteroid therapy targeted at these epithelial cells is 
effective for treatment of asthma as well as rhinitis.  (14) 
There are systemic components to this Th2 inflammation as well, reflected by 
markers in the circulation.  Inflammatory activity in the airways triggers eosinophil and 
basophil recruitment from the bone marrow, producing a significantly higher number of 
these cell types in the peripheral blood. (15)  IL-4 and IL-13 induce B-lymphocytes to 
produce IgE, which is elevated in the serum of asthmatics. (16)  Blocking the effect of IgE 
systemically with omalizumab (anti-IgE) has been shown to be an effective adjunctive 
therapy for asthma in uncontrolled atopic patients with elevated IgE levels and allergen 
hypperactivity proven by testing. (17)  A number of other inflammatory markers in the 
serum have also been shown to be associated with asthma, including IL-5 (18), eosinophil 
cationic protein (19), IL-8, and TNF-α. (20)  Asthma has also been associated with diseases 
of other organ systems including atopic dermatitis, gastroesophageal reflux disease, 
inflammatory bowel disease, obesity, obstructive sleep apnea, and cardiovascular disease. 
(3) 
Current Modalities of Treatment 
The current cornerstone of recommendations for the management of asthma is the 
control of symptoms and prevention of adverse outcomes.  The Healthy People 2010 
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initiative focuses on increasing the proportion of asthmatics receiving formal education and 
appropriate care according to National Asthma Education and Prevention Program (NAEPP) 
guidelines.  However, it fell short of its stated goals, particularly in patients receiving an 
asthma management plan with specific instructions on how to change the amount or type of 
medicine taken, when to call a doctor for advice, and when to go to the ED.  Report of 
receiving this asthma education differed among groups, with generally higher rates among 
children than adults and among non-Hispanic black patients than non-Hispanic white and 
Mexican patients. (1) 
Medical management is divided into two categories – controller medications to 
reduce inflammation and “rescue” medications to reverse bronchospasm.  NAEPP 
guidelines recommend a stepwise treatment to asthma.  Children with intermittent asthma 
are treated with rescue medications as needed.  Albuterol, a short acting bronchodilator 
(SABA) that relaxes airway smooth muscle and reverses bronchoconstriction, is the 
cornerstone of such treatment.   
Children with persistent asthma, as well as children whose asthma is not well-
controlled, require “step ups” of treatment to daily controller medication.  Not well-
controlled asthma is defined by frequent symptoms and/or frequent use of SABAs (>2 
days/week), nighttime awakenings, interference with normal activity, and 2 or more 
exacerbations in a year requiring oral corticosteroid therapy. (21).  The Asthma Control 
Test (ACT) is a paper and web-based validated tool developed to assess level of disease 
control over the last 4 weeks; the adult version assesses limitation at work or school, 
shortness of breath, frequency of symptoms, frequency of rescue inhaler or medication use, 
and self rating of control. (22)   A pediatric version, validated for ages 4 to 11, includes four 
questions directed at the child with a face and corresponding text (rate asthma today, 
problem with exercise, cough, wake up at night), and 3 questions directed at the parent 
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(frequency of daytime symptoms, frequency of wheeze, and frequency of nighttime 
awakening).   In both tests, a score of 19 or less suggests poor asthma control.  (23)   Data 
supports that the minimally important difference for the ACT is 3 points. (24) 
Daily controller medications include therapies targeting asthmatic inflammation, 
such as inhaled corticosteroids (ICS), leukotriene modifiers, and the anti-IgE antibody 
omalizumab.  Long acting bronchodilators (LABAs) are also used in conjunction with ICS 
therapy for patients with persistent asthma that do not achieve good control with inhaled 
ICSs alone. 
Adenotonsillectomy in Children and its Effect on Asthma 
Adenotonsillectomy is one of the most common surgical procedures performed in 
children.  The superior part of the pharynx contains a ring of lymphoid tissue consisting of 
the pharyngeal tonsils on the posterior wall of the nasopharynx (commonly known as the 
adenoids) and two palatine tonsils (commonly known as “tonsils”) on either side of the 
oropharynx.  The tonsils and adenoids are most active between the ages of 4 and 10, and 
then usually involute starting at puberty.  As lymphoid tissue exposed to the environment, 
the tonsils and adenoids can directly transport environmental antigens encountered on 
their surfaces to the lymphoid tissue on the interior. (6) 
There were 530,000 tonsillectomies (with or without adenoidectomy) performed on 
children under fifteen in 2006; although this number is less than it once was (1.4 million in 
1959), the prevalence of the procedure has increased in recent years (315,000 in 1996). 
(25)  Indications for tonsillectomy have shifted over time.  The most common current 
indication is hypertrophied tonsillar tissue that causes upper airway obstruction “sleep-
disordered breathing.”  Symptoms and signs can include snoring and sleep fragmentation, 
leading to daytime exhaustion, with possible effects on behavior and/or school 
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performance.  Obstructive sleep apnea (OSA) is diagnosed when there is a complete 
blockage of the airway during sleep and intermittent hypopnea, leading to hypercarbia and 
hypoxia; the gold standard for diagnosis of OSA is overnight polysomnography. (6) Recent 
studies have also shown activation of inflammatory pathways as a result of sleep disordered 
breathing, including activation of cytokine cascades. (26)  Adenotonsillectomy is a well 
proven intervention for sleep disordered breathing in children. (27)   
Recurrent or persistent pharyngitis is the second most common indication.  Classic 
studies have used as criteria for tonsillectomy: 7 infections in one year, 5 in two years, 9 in 
three years, or chronic tonsillitis defined as sore throat lasting for at least 3 months. (28)  
Studies have shown there to be a benefit from adenotonsillectomy in reducing the number 
of infections; however, the improvement in a recent meta-analysis was not dramatic. (29)  
The exact role of tonsillectomy as therapy for recurrent pharyngitis remains somewhat 
controversial. 
Other less common indications include peritonsillar abscess unresponsive to 
medical therapy and, rarely, suspected malignancy. (6, 28) 
The “one-airway hypothesis” suggests that  abnormally inflamed tonsillar tissue, 
whether due to infection or due to hypertrophy and causing sleep disordered breathing, 
may contribute to upper airway inflammation that is reflected in the lower airways and 
thus may contribute to asthma.  Studies report conflicting results on the relationship 
between obstructive sleep apnea and asthma; though studies outside of the U.S. report 
asthma as a risk factor for a diagnosis of OSA (30), one U.S. study found that asthma was not 
a risk factor and in fact parental report of asthma decreased the risk of an OSA diagnosis. 
(31)  Nonetheless, it is possible that the hypertrophied or inflamed tonsillar lymphoid tissue 
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chronically or intermittently triggers airway inflammation and asthma; removing the 
tonsils would eliminate this trigger. 
A handful of observational studies support this concept. (7)  One early study 
demonstrated that up to 88% of patients with asthma experience a significant improvement 
in symptoms and reduce or eliminate asthma controller or rescue medication usage 
following adenotonsillectomy.(8)  A recent retrospective chart review of 93 children with 
asthma who underwent tonsillectomy for standard indications showed significant 
improvements in multiple asthma measures including mean hospital visits, systemic steroid 
administration, asthma medication use, and childhood asthma control test scores.(9)  In 
addition, a recent cohort study identified children with poorly-controlled asthma and 
referred them for polysomnography; if diagnosed with OSA, the children were offered 
adenotonsillectomy.  Post-tonsillectomy data for 35 children showed a significant 
improvement from adenotonsillectomy in asthma control, defined by asthma exacerbations, 
weekly rescue medication usage, asthma symptom score, and FEV1.(10)   Limitations of the 
study include lack of control groups (non-surgical, well-controlled asthma, non-asthmatics), 
a study design that included identification of OSA as “part of clinical routine”, loss to follow-
up, and lack of time frame indicated. (32) 
Whether or not this reported improvement is a purely clinical effect on the airway, 
or is a biological effect on airway inflammation and asthmatic pathogensis, has not yet been 
studied.   
Chitinases in Asthma 
Chitinases are a family of hydrolases detectable in the circulation that correlate with 
inflammation and disease activity in a number of chronic diseases including asthma and 
adenotonsillar disease. (33)  These proteins bind to or cleave chitin, the second most 
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abundant polysaccharide in nature and the major structural polymer in cell walls of bacteria 
and fungi, the shells of crustaceans, and the exoskeletons of arthropods such as cockroaches 
and dust mites, common allergic triggers in asthma. Animal models have shown that chitin 
can have either pro- or anti- inflammatory effects – when delivered orally or intransally, 
chitin inhibits Th2 inflammation; when delivered to the lung in isolation, chitin enhances 
Th2 inflammation.  These results suggest a complex interplay between environmental chitin 
exposure and the pathogenesis of asthma. (33, 34) 
Though mammals do not have chitin, they have conserved chitinase proteins that 
break down chitin from the environment.  Like chitin itself, there is evidence in animal 
models as well as humans that chitinase proteins can act as up- or down-regulators of the 
innate immune response by interacting with and degrading chitin and by modulating the 
host’s inflammatory response. Chitinases may act as the link between environmental chitin 
exposure and the Th2 inflammatory response. (33, 35)  There are two major chitinases in 
humans; chitotriosidase (CHIT1) is a true enzyme with the ability to hydrolyze chitin, while 
YKL-40 (CHI3L1) is a chitinase-like protein, which has the ability to bind to chitin but not to 
degrade it.  Both chitinase activity and YKL-40 levels are demonstrated to be elevated in the 
bronchoalveolar lavage fluid of children with asthma. (36)  
Chitotriosidase has been shown to be the primary active chitinase enzyme in the 
human lung. (37) It also is the only active chitinase in the peripheral blood, meaning that 
measurement of serum chitinase activity is a surrogate for measurement of chitotriosidase 
levels. Serum chitinase activity has been shown to be elevated in a number of disease states, 
including Gaucher’s disease, thalassemias, arteriosclerosis, and coronary artery disease.  It 
is elevated in the bronchoalveolar lavage fluid in certain lung diseases including sarcoidosis 
and interstitial pulmonary fibrosis. (33) 
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Chitotriosidase is overexpressed in adenoid tissue of children undergoing 
adenotonsillectomy with concurrent chronic rhinosinusitis, otitis media with effusion, and 
allergic rhinitis compared to subjects without concomitant upper airway disease. (38)   
Proteins in the chitinase family have also been demonstrated as markers of the 
systemic component of asthmatic disease.  A cross-sectional study of children with allergic 
and non-allergic asthma showed that chitotriosidase levels were elevated in the serum of 
individuals with asthma children versus control subjects. (39)  YKL-40, the chitinase-like 
protein, has been reported to be elevated in the serum of individuals with asthma and levels 
correlate positively with disease severity. Specifically, Chupp et al. showed that levels 
correlated with poor pulmonary function tests, subepitithelial basement membrane 
thickening, and airway remodeling in the Paris cohort. (40)  Members of the chitinase 
family may reflect a biological link between upper airway inflammation alleviated by 
adenotonsillectomy and the effect of environmental triggers in the pathogenesis of asthma.    
Chitinase Genetics 
Studies have shown mixed results on the role of genotypes for chitinase proteins on 
asthma.  CHIT1, the gene encoding chitotriosidase, has a polymorphism containing a 24-
base pair duplication in exon 10 (rs3831317) that produces a non-functional protein.  The 
allele is highest frequency in East Asian, Middle Eastern, and Indian populations. (33)  Lee 
et al. reported associations between the 24-bp duplication and positive TB tests in 
Europeans but not in Asians, and an association with three or more atopic diseases (asthma, 
allergic rhinitis, atopic dermatitis, allergies to drugs, cosmetics or food, and frequent 
sneezing, watering, or nasal congestion) in Asians but not in Europeans. (41)  Though 
significant, the p-values were modest, the definition of atopy broad, and there were 
differences among ethnic groups, raising the possibility of a false positive result. (33)  
Vicencio et al. reported in an observational study 6 asthmatic pediatric patients with fungal 
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sensitization, all of whom had the CHIT1 24-bp duplication. (42)  However, other larger 
studies have reported no association between the allele and presence of asthmatic disease, 
emergency room visits for asthma exacerbations, or hospitalizations due to asthma. (43, 44) 
A stronger association between asthma and the genotype of CHI3L1, the gene 
encoding YKL-40, has been reported.  CHI3L1 contains a promoter SNP (rs4950928, 
131CG); the C allele (major allele) is associated with elevated YKL-40 levels.  A study 
looking at frequency of the SNP in a founder population of European descent (the 
Hutterites) as well as multiple other case-control populations showed an association of the 
C allele with asthma prevalence, poor pulmonary function, and bronchial 
hyperresponsiveness.  (45)  Cunningham et al., in a large cross-sectional study of pediatric 
patients with asthma, showed that the G allele (minor allele) was protective for asthma-
related hospitalizations. (46)  A study of Korean children demonstrated an association 
between C haplotype and atopy, though there was no association with asthma.  (47) 
Gene Expression in Asthma 
Gene expression profiling techniques allow for the high-throughput identification of 
novel genes and pathways involved in disease pathogenesis.  This technique has been 
increasingly used in asthma to study its complex etiology.  There exist a number of studies 
looking at human tissue in asthmatics. (48)   
A number of studies have examined bronchial biopsy tissue, as the principal tissue 
affected in asthma.  Liprase et al. used microarray technology to compare gene expression 
from 4 subjects with mild asthma (who were not on ICSs) and control subjects.  They found 
that 20 genes were up-regulated and 54 genes were down regulated, including immune 
signaling molecules, extracellular proteins, immune response proteins, and intracellular 
signaling molecules.  Some genes were identified that were known to be involved in asthma 
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pathogenesis, including nitric oxide synthase 2A (NOS2A), glutathione peroxidase 3 (GPX3), 
and T-cell receptor α (TCRα); others were newly implicated including arachidonate 15-
lipoxygenase (ALOX15), which may be involved in airway remodeling, and fractalkine 
receptor (CX3CR1), previously found to be elevated in peripheral CD4+ lymphocytes of 
asthmatics, serpin proteinase family inhibitors, some of which have been found to be 
elevated in the serum of asthmatics. (49)  Another study using RT-PCR of bronchial samples 
confirmed a number of genes identified by Laprise et al. and also identified others, including 
the Na+ K+ Cl- co-transporter (NKCC1) which showed eightfold increased expression in 
asthmatics. (50) Woodruff et al. studied airway epithelial cells in adults with asthma in a 
randomized trial of inhaled corticosteroids.  A calcium-activated chloride channel (CLCA1), 
periostin, and serine peptidase inhibitor B2 were up-regulated in asthmatics.  
Corticosteroid therapy down-regulated expression of the three genes, and high baseline 
expression of the three predicted improvement. (51)  The limitation of bronchial studies is 
that bronchial biopsy samples are often heterogeneous due to differing biopsy techniques 
and patterns of disease. (48) 
Other studies have looked at upper airway epithelial cells.  Lilly et al. examined 
individuals with mild asthma and subjected them to an allergen challenge.  A number of 
genes previously implicated in asthma were found to be differentially expressed genes 
between pre- and post-challenge airway epithelium, including included IL-1β, IL-8, TNF-α 
induced protein 6, lipocortin-1, and plasminogen activator inhibitor 2. (52)  Guadajero et al. 
recruited 10 children with stable asthma, 10 children experiencing an acute asthma 
exacerbation, and 10 nonatopic children without asthma.  They used a pooled microarray 
analysis to compare expression profiles of nasal respiratory epithelial cells from each group.    
37 immune-related genes were among the up-related genes in the acute-exacerbation 
group, with 9 cilia-related genes consistently down-regulated. (53)  Limitations for 
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epithelial studies include sample heterogeneity, questionable representation of the lower 
airway in the nasal epithelia, and confounders including rhinitis and atopy. (48) 
Given that asthma is a systemic disease, a number of studies have looked at 
expression in circulating cells.  Brutsche et al. examined peripheral blood mononuclear 
cells.  They developed gene expression based score (composite atopy gene expression, or 
CAGE) to predict atopy with 96% sensitivity and 92% specificity; the score is based on the 
expression of 10 genes including IL-1 receptor, IL-6, and the IFN-αβ receptor.  Additionally, 
a number of B-cell isotype, cell survival, and IgE production genes were up-regulated in 
severe asthma. (54)  Aoki et al. performed expression profiling of genes related to asthma 
exacerbations in the peripheral blood mononuclear cells of children.  They found during an 
exacerbation 137 up-regulated and 16 down-regulated genes; 62 were also differentially 
expressed during an upper respiratory infection.  Many of these genes were related to 
immune responses to external stimuli, supporting the notion that asthma exacerbations and 
respiratory infections share a common mechanism. (55)  In peripheral blood lymphocytes, 
Hansel et al. found up-regulated genes in asthma to include TGF-β and genes involved in T 
cell activation. (56)  The involvement of TGF-β was confirmed by another microarray study 
of CD4+ lymphocytes in asthmatics versus controls. (57) 
Hypothesis and Aims 
Asthma is a heterogeneous disease of the lower airways that remains a significant 
healthcare concern for the pediatric population despite numerous public health and 
pharmacologic advances to control the disease.  Recent studies have shown a link between 
upper airway inflammation and asthma, and respiratory infection and allergen exposure are 
frequently indicated as triggers for asthma exacerbations in pediatric patients.  
Adenotonsillectomy is common surgical procedure in children performed to address upper 
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airway hypertrophy, infection, and inflammation.  A number of observational studies have 
demonstrated a positive clinical effect of this surgery on asthma control; however these 
studies have limitations due to study design, and no previous studies have examined the 
effect of adenotonsillectomy on biomarkers on inflammation.  Chitinases have been 
implicated in the pathogenesis of inflamed adenotonsillar tissue, and in the presence and 
severity of asthma, and may reflect a biological link between upper airway inflammation 
alleviated by adenotonsillectomy and the effect of environmental triggers in the 
pathogenesis of asthma.  Gene expression profiling in the blood and upper airway tissue of 
patients undergoing adenotonsillectomy may be able to characterize biological changes due 
to the procedure and identify genes uniquely affected in children with asthma undergoing 
the procedure. 
We hypothesize that asthmatic control will improve in children undergoing 
adenotonsillectomy.  Using chitinase levels and gene expression profile data in the serum 
and upper airway, we postulate it is possible to characterize unique biological changes 
among children with improvement in asthma control undergoing the surgery compared to 
children without improvement and children without asthma. 
Specific Aims 
1. Conduct a prospective observational study of pediatric patients, with and without 
asthma, undergoing tonsillectomy for standard indications.  Asthma will be 
characterized by clinical symptoms and pulmonary function tests.  Serum 
biomarkers including chitotriosidase activity, YKL-40 levels, and IgE will be 
measured, and expression profile data of tonsillar tissue, nasal epithelium, and 
peripheral blood will be collected.  Questions, PFTs, serum biomarkers, and 
peripheral blood expression data will be repeated 6 months post-operatively. 
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2. Compare asthma control pre- and post-operatively, and retrospectively identify any 
clinical characteristics pre-operatively that predict a positive outcome. 
3. Determine the changes in chitotriosidase activity, YKL-40 levels, and genetic 
expression profiles pre- and post-operatively of asthmatics and non-asthmatics 
undergoing tonsillectomy.   CHIT1 and CHI3L1 genotypes will be determined at 
baseline. 
4. Correlate clinical findings (in Aim 2) with biomarker and genetic findings (in Aim 3) 
to determine if there is (a) a characteristic biological response in patients who see 
symptom improvement after tonsillectomy and (b) a set of biomarkers that could be 
measured pre-operatively that would predict clinical improvement after operative 
intervention. 
Methods 
Enrollment and Follow-up 
Pediatric patients ages 2-18, with and without asthma, who were undergoing 
adenotonsillectomy for standard indications at Yale New Haven Children’s Hospital and 
North Haven Surgery Center were recruited over a 13-month period.  Informed parental 
consent and child assent for patients age ≥ 7 were obtained.    All procedures were approved 
by the Yale University and the Yale New Haven Hospital Human Investigation Committee. 
On the day of surgery, a study member administered a questionnaire to the subject’s 
parent.  Definition of asthma was based on a previous physician diagnosis prior to surgery.  
The questionnaire consists of pulmonary history, including history of asthmatic disease; a 
list of common triggers with examples including infection, allergy, household (dust, smoke, 
carpet), environment (pollution, cold weather), and exercise; Emergency Department (ED) 
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or urgent care visits related to asthma; steroid courses; comorbidities including history of 
sinus disease, gastroesophageal reflux disease (GERD), allergic rhinitis, and eczema; 
medications, including compliance, perception, and frequency of usage in the last 4 weeks; 
and days of school missed and parental days of work missed due to the child’s asthma and 
other illnesses.   Subjects with asthma also completed an age-appropriate version of the 
Asthma Control Test (ACT), with the assistance of parents or guardians as needed. (22, 23)  
Adult ACT scores were rescaled from maximum 25 to 27 in order to compare to childhood 
ACT scores, which also have a maximum score of 27.  Children were defined as having 
poorly-controlled asthma at baseline by one of the following criteria, based on asthma and 
ACT guidelines: pediatric or adult ACT < 20, two or more ED/urgent care visits in the 
previous year, two or more oral corticosteroid courses in the previous year, or using SABA 
medication more than twice per week in the last month. (21)  Children age six and above 
completed Pulmonary Function Testing (PFTs) if they were able to comply with the 
instructions given. Intraoperatively, the anesthesiology team obtained venous blood in 
serum. 
Six months after surgery, parents were contacted by telephone or email.  Primary 
study outcome for children with asthma was measured by retesting an ACT score.  The 
follow-up questionnaire was also administered to parents, with rates calculated for 
variables measuring number of incidences over a given time (Emergency/Urgent Care 
visits, steroid courses, school and work days missed). Changes were used to calculate a 
composite variable of improvement in asthma control, with improvement defined as one of 
the following: increase in ACT score of 3 or greater, decreased rate of Emergency/Urgent 
Care visits, a decreased rate of oral corticosteroid courses, or a decrease in rescue short 
acting bronchodilator (SABA) usage in the previous month.  PFTs were also repeated for 
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those study subjects with initial testing.  Repeat blood samples were drawn at this time as 
well.  Study participants were compensated for completing follow-up.  
Chitotriosidase Activity, YKL-40 levels, and IgE levels 
Serum chitinase activity was determined using a fluorimetric assay as previously 
described, and reported as nmol/mL/hr. (37, 58)  Briefly, 44 µmol/L substrate was prepared by 
mixing 1 mg 4-methylumbelliferyl-β-D-N,N’,N’’-triacetylchiotrioside in 2mL H2O and 26.9 
mL of McIlvain buffer, then sonicated and incubated at 37°C until dissolved.  Serum was 
immediately spun down at 1500rpm for 10 min after collection; the supernatant was 
extracted and stored at -20°C.  To measure the enzyme activity, 180µL substrate was mixed 
with 20µL serum.   The mixture was incubated at 37°C for 30 minutes.  2mL Stop Solution 
(0.3mol/L glycine-NaOH, pH 10.6) was added to each sample, and then each sample was 
measured using fluorometry (Sequioa Turner).  Enzyme activity was calculated in 
nmol/mL*h using a standard curve. 
YKL-40 levels were determined using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (MicroVue), as previously described. (40).  Briefly, serum 
from each subject was measured in duplicate.  100 µL capture solution was added to 20 µL 
of each sample in plates included with the kit.  After 1 hour incubation at room temperature, 
sample wells were emptied and then washed three times with 300 µL wash buffer.  100 µL 
enzyme conjugate was then added to each well.  Samples were incubated for another hour 
at room temperature, followed by three more washes.  100 µL substrate buffer was then 
added to each well.  After incubation for 1 hour at room temperature, 100 µL stop solution 
was added to each sample.  Levels were measured by plate reader (BioTek) based on a 
standard curve.  Median values between sample duplicates are presented.  If measured 
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levels between the duplicates showed a more than 30% discordance, the sample was 
repeated. 
IgE levels were measured by commercially available services (Healthpoint 
Diagnostix, Inc).   
Genotyping 
We extracted DNA from blood using the QuickGene DNA whole blood extraction kit 
(Fujifilm).  Briefly, blood was stored in Solution A tubes and immediately refrigerated at 
4°C.  300 µL protease and 2.5 mL lysis buffer were added to each 2 mL blood, and the 
samples were incubated 30-40 minutes at 56°C.  2.5 mL 100% EtOH was added to 
neutralize the lysis buffer, and then the DNA was extracted using the QuickGene system.  
The concentration of DNA was confirmed using the NanoDrop spectrophotometry system. 
We examined the prevalence of a promoter SNP in the CHI3L1 gene encoding YKL-
40, rs4950928 (131 CG).  The C allele has been shown to be associated with elevated 
levels of YKL-40.  The SNP was genotyped with differentially labeled primers containing the 
C and G allele using TaqMan q-PCR Assay-on-Demand (ABI).  Briefly, 1 µL of sample DNA 
was added to an Assay Mix that included the labeled rs4950928 primers, dNTPs, and 
enzyme.  After the PCR reaction was complete, each sample was scanned (Applied 
Biosystems 7500 Fast Real Time-PCR); based on the incorporated label, each sample was 
identified as having the C or G SNP. (45) 
We also examined the prevalence of the 24-bp exon 10 duplication in the CHIT1 
gene encoding chitotriosidase.  The duplication results in a nonfunctional protein.  We 
performed PCR on the DNA using primers for exon 10; the duplication genotype was 
differentiated from the wild-type using gel electrophoresis.  Briefly, 1 µL of sample DNA and 
exon 10 primers were added to premixed solutions with dNTPs and polymerase.  After the 
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PCR reaction was complete, gel electrophoresis was performed; based on segment length, 
each sample was determined to either be wild-type or include the duplication. 
Statistical Analysis 
All clinical and experimental data was uploaded onto the Yale Center for Asthma 
and Airway Diseases online database.  Statistical analyses were performed using IBM SPSS 
Statistics version 19.  Nominal data was compared using Fisher’s Exact test and Pearson’s 
chi-square; all scaled data was confirmed to be of a non-normal distribution with the 
Shapiro-Wilk test for normality; thus, non-parametric methods including Mann-Whitney U 
and Wilcoxon Signed Rank Tests were employed. p-values <0.05 were considered 
significant. 
RNA Extraction 
 Tonsillar and nasal epithelial tissue were immediately stored in 500 µL RNALater™ 
(Invitrogen) solution and refrigerated at 4°C overnight to allow for the solution to permeate 
the tissue, then stored long term at -80°C. 
 To extract DNA from tonsillar tissue, 50-100 mg sample was cut and transferred to a 
fresh 14mL Falcon tube.  1 mL Trizol solution (Invitrogen) was added.  The sample was 
homogenized using sonication for 30 seconds, with 15 second PBS washes of the sonication 
probe between samples.  The homogenized mixture was then transferred to a 1.5 mL 
centrifugation tube.  The solution was spun down at 12000g x 10 min at 4°C, and then 
incubated at room temperature for 5 minutes.  750 µL supernatant (aqueous phase) was 
extracted; 150 µL chloroform was added.  After vortexing to mix, the sample was set to 
incubate at room temperature for 3 minutes.  Afterwards, it was spun down again at 12000g 
x 15 min at 4°C.  At this point, 300 µL supernatant was transferred to a DNA column from 
the RNA Easy Mini Plus Kit (Qiagen). 
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 The DNA column was spun at 10000 rpm x 30 sec at room temperature.  Flow 
through was collected and the column discarded.  300 µL (1:1 volume) 70% EtOH was 
added to the flow through and mixed well by pipetting.  This solution was transferred to the 
RNA Column from the kit. It was spun at 10000 rpm x 30 sec at room temperature.  With the 
RNA in the column, the flow through was discarded.  700 µL RW1 Wash Buffer was added 
and spun down at 10000 rpm x 30 sec; another two washes were completed with 500 µL 
RPE Wash Buffer and spun down at 10000 rpm x 30 sec; this was followed by a dry spin of 
10000 rpm x 2 min.  Lastly, 50 µL water was added to the column and spun down at 10000 
rpm x 1 minute to elute the RNA.  The presence of RNA and concentration was measured 
using the NanoDrop spectrophotometer; if more concentration was desired, the 50 µL 
elution was re-spun through the column for a higher RNA yield.   
 This method was a modification over previously attempted methods to isolate the 
RNA using Trizol solution (Invitrogen).  At first, samples were stored in Trizol.  RNA was 
extracted after homogenization, separation of the aqueous phase once chloroform was 
added, and then purified by spinning down to create an RNA pellet.  However, it was found 
that despite good concentration, RINs (RNA Integrity Numbers) were poor, indicating RNA 
degradation.  This method was modified to use the Qiagen RNA Easy Mini Plus Kit for 
column purification of the RNA, rather than using an RNA pellet, but RINs were still poor.  
Finally, RNALater™ was used instead of Trizol as the storage solution for the tissue samples.  
This drastically improved RINs, though there was found to be some protein contamination 
(low A260/A230, as measured by NanoDrop).  The final modification to create the protocol 
as listed above, was adding an extra spin down step after homogenization but before adding 
chloroform to remove insoluble protein precipitate from the Trizol mixture before 
separation of layers.  This procedure allowed us to consistently produce high 
concentrations of high quality RNA from tonsillar samples.  However, the first 60 tonsillar 
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samples collected were stored in Trizol and therefore have low quality RNA that was not 
used in expression analysis. 
 A similar process was employed to extract RNA from nasal epithelial tissue.  Again, 
tissue was stored in 500 µL of RNALater™, and refrigerated at 4°C for one night before long 
term storage in -80°C.  Preparation for extraction included mixing 3.5 µL β-mercaptoethanol 
and 350 µL RLT buffer (Qiagen RNA Easy Mini Plus Kit).  The nasal swab brush was then 
transferred from the RNALater™ to the RLT buffer with β-mercaptoethanol and allowed to 
sit on ice for 30 minutes.  After incubation, the mixture, with the swab, was vortexed for at 
least 15 seconds.  The solution was then transferred to a QIAShredder column.  Finally, the 
original tube with the swab was spun at low speed for 1 min, and any remaining solution 
was added to the QIAShredder column.  The QIAShredder was spun at 10000rpm x 2min; 
flow through was transferred to the DNA column and the procedure was carried out with 
the Qiagen RNA Easy Mini plus Kit, exactly as stated above for the tonsillar tissue RNA 
extraction.  Again, this method was a modification after samples that were stored in Trizol 
produced low RIN numbers.  The first 60 samples collected were stored in Trizol and 
therefore have low quality epithelial RNA. 
 To extract RNA from whole blood, peripheral blood was collected in a Tempus™ 
tube (Applied Biosystems) and stored at -20°C.  It was found to be important that the blood 
was mixed well with the solution in the Tempus™ tube immediately after collection to 
ensure RNA preservation.  To extract the blood RNA, 3 mL PBS and the peripheral blood 
were mixed and vortexed, then spun at 3000g x 30 minutes at 4°C.  The supernatant was 
discarded after the spin (though kept in case RNA extraction failed and needed to be 
repeated).  Tubes were air dried, facing upside down on a paper towel for 5 minutes, then 
dried with a cotton swab (being careful not to swab the bottom of the tube, the location of 
the RNA pellet).  Using the Total RNA Purification Kit (Norgen), 400 µL Lyse Buffer was 
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added to each sample and vortexed.  200 µL 100% EtOH was added and mixed by pipetting.  
The solution was then transferred to the Norgen RNA extraction columns.  Samples were 
centrifuged at 13000 rpm x 1min at room temperature.  The flow through was discarded.  
Each sample was washed three times with 400 µL Wash Buffer, 13000 rpm x 1 min for the 
first two washes and 13000 rpm x 3 min for the last wash.  After a dry spin of 13000 rpm x 
2 min, 50 µL Elution buffer was added.  The sample was let to sit for 1-2 minutes, and then 
spun at 13000 rpm x 2 min.    
Extracted RNA from all tissue types was sent to the Keck Laboratory on the Yale 
West Campus, where RNA quality was measured by looking at the integrity of 18S and 28S 
ribosomal RNA.  Their integrity indicated good sample quality; their absence reflected RNA 
degradation in the sample.  The computer generated an RNA Integrity Number (RIN) for 
each sample based on the 18S and 28S rRNA integrity; RINs ≥ 6 were generally considered 
acceptable; however if spectrophotometric peaks for the 18S and 28S rRNA looked 
acceptable to the eye but the computer calculated a low RIN or could not calculate a RIN, the 
sample was also included. 
Microarray Analysis 
 Affymetrix™ Gene Chip Human Exon 1.0 ST microarrays were used for analysis.  
Gene Chip Human Exon 1.0 ST Arrays contain 5,362,207 features with 1.4 million probesets 
that cover over one million exon clusters, 289,961 known genes by mRNA transcript, and 
665,175 genes by Expressed Sequence Tags.  The Keck Laboratory performed all 
microarray readings according to Affymetrix protocols.  Blood samples were cleaned of 
hemoglobin prior to reading.  All samples underwent cDNA amplification using PCR prior to 
read.   
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Scanned output files were analyzed using Affymetrix™ software, and cell image data 
files were loaded into GeneSpring GX software version 11 (Agilent).  Data were log-
transformed, normalized, and baseline-converted was performed to median values by RMS 
for each individual analysis group (tonsil samples, nasal epithelial samples, baseline blood 
samples, and matched baseline & follow-up blood samples) Quality control on each set was 
performed using PCA plot.  Interpretations were performed for baseline blood, nasal 
epithelium, and tonsil samples according to improvement in asthma control.  Differential 
gene expression was determined by t-test; genes for analysis were limited to differential 
expression p<.05 and fold change > 1.5.  No post hoc testing for multiple comparisons, 
including Benjamini-Hochberg method, was used due to insufficient results after 
corrections.   Interpretations for improved control, not improved control, and control 
subjects were also performed on matched baseline and follow-up blood samples; 
differential gene expression was determined by paired t-test without post hoc testing for 
multiple comparisons; again, genes for analysis were limited to differential expression 
p<.05 and fold change >1.5.  Gene Ontology categories and pathways that were well 
represented among the gene lists were determined, with p < 0.1. (53, 59)  Individual genes 
were searched for relevance in the NCBI Gene databases. 
Results  
Cohort Characteristics 
130 patients total undergoing adenotonsillectomy were enrolled, ages 2-18, over a 
13 month period.  66 subjects had diagnoses of asthma; 64 subjects were controls (Figure 
1).  75% of study participants had a primary indication of tonsillar hypertrophy, including 
symptoms of sleep-disordered breathing, for surgery.  23% of participants had a primary 
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indication of recurrent tonsillitis/infection for surgery; there was no significant difference 
between asthma and control groups.  Compared to controls, children with asthma had 
higher incidence of expected comorbidities including atopy (seasonal allergies and/or 
eczema) and a history of GERD, and were more common of Hispanic origin (p=0.01, 0.01, 
0.03, respectively). (60)   Children with asthma had a lower median FEV1 (p=0.03), 
consistent with a physician diagnosis of asthma (Table A).  Baseline ACT scores ranged from 
6-27, with a median of 22 (interquartile range 16-22).  46 children completed the pediatric 
ACT and another 5 children completed the adult ACT at baseline; 15 children never 
completed a baseline ACT.  29 subjects were administered ACT questionnaires following 
surgery during the follow-up period, rather than prior to surgery.  These families completed 
the ACT prior to follow-up by phone or at the follow-up appointment.  There was no 
relation between indication for surgery and baseline ACT score.  38 out of 66 (58%) had 
poorly-controlled asthma (ACT < 20, ≥ 2 ED/urgent care visits in the previous year, ≥ 2 oral 
corticosteroid courses in the previous year, or using SABA medication more than twice per 
week in the last month). 
Follow-up was achieved in 81% of the enrolled subjects (N=105), 58 subjects with 
asthma and 47 control subjects.  Bloodwork was obtained for 122 participants (94%) at 
baseline; 67 parents gave consent (64% of those achieving follow-up) to have bloodwork 
performed post-operatively.  Patients were primarily lost to follow-up due to failure to 
respond or unable to contact (moved or changed phone number).  Mean time to follow up 
was 7.0 months (range 5-12, SD 1.5), and was not statistically different between study 
groups.  Follow-up rate was also not statistically different for patient age, gender, race, 
ethnicity, or indication for tonsillectomy. 
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Effect of Adenotonsillectomy on Asthma Control 
 Asthma control and asthma-related healthcare utilization were significantly 
improved after adenotonsillectomy.  There was a clinically significant improvement in ACT 
scores after 6 months (median increase from 22 to 25, p< 0.001, Figure 2a) and subjects 
with asthma reported significant decreases in the rate of ED/Urgent Care visits, oral 
corticosteroid courses, missed school days due to asthma, and total missed parental work 
days due to illness (Table B).   An improvement in score of 3 or more was considered 
clinically significant, previously shown to be the minimally important difference in score. 
(24)  Of 35 individuals with rescaled ACT scores < 25, 24 subjects (69%) had increases in 
score of 3 or more (p< 0.001, Figure 2b).  12 of 27 children (44%) on controller medications 
for asthma at baseline were no longer on controller medication at follow-up.  Two children 
“developed” asthma during the follow-up period; these children were characterized as 
controls since they were classified as without asthma at the time of surgery.  PFT scores did 
not significantly change for either study group between baseline and follow-up.  Subgroup 
analysis of children with poorly-controlled asthma at baseline demonstrated a more 
pronounced increase in ACT score, from a median of 18 to 24. (21) 
The composite variable of improvement in asthma control was defined by fulfilling 
one of the following categories: increase in ACT score of 3 or greater, decreased rate of 
Emergency/Urgent Care visits, a decreased rate of oral corticosteroid courses, or a decrease 
in rescue short acting bronchodilator (SABA) usage in the previous month.  Of the 48 
children with asthma who were not already maximally controlled at baseline, and therefore 
had room to improve (pediatric ACT <25, adult ACT <23, one or more ED/urgent care visit 
in the previous year, one or more oral corticosteroid course in the last year, or using SABA 
medication in the last month), 36 (75%) had an improvement in symptoms in at least one 
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category.  When limited to the 34 subjects with poorly-controlled asthma at baseline, 29 
(85%) had an improvement in symptoms in at least one category. 
Improvement in asthma control, using the composite variable, did not significantly 
correlate with baseline patient characteristics including age, years since asthma diagnosis, 
comorbidities, smoke exposure, indication for adenotonsillectomy, or PFTs.  In the 
subgroup analysis of children with poorly-controlled asthma at baseline, asthma control in 
all 19 subjects who listed “Environment” as a trigger improved, while control in only 10 of 
15 (67%) of those who did not improve (p=0.01).  Improvement in control was also 
significantly associated with a lower baseline ACT score among those with poor control at 
baseline (median score of 22 for subjects with improved asthma control versus score of 16 
for those without improved control, p< 0.05). 
Analysis of Chitinase Genotypes and Levels 
 Genotypic analysis of the CHIT1 24-bp exon 10-duplication showed a significantly 
higher allele frequency of the mutation in the asthmatic population undergoing 
adenotonsillectomy, 26% vs. 14%, (t-test p< 0.02, Figure 3).  Analysis of the CHI3L1 
rs4950928 (131 CG) promoter SNP showed a lower allele frequency of the minor G allele 
in the asthma populations (14% vs. 18%, respectively), a result consistent with previous 
findings though not significant in this study (p=0.39).  Of note, CHIT1 and CHI3L1 genotypes 
did not significantly associate with gender, race, or ethnicity.  CHIT1 and CHI3L1 genotypes 
also did not significantly associate with improvement in asthma control following surgery. 
Chitinase activity was evaluated at baseline and follow-up.  Corresponding to the 
increased prevalence of the exon 10-duplication in children with asthma, chitinase activity 
was significantly lower in the asthmatic population, median 3.1 nM/ml*hr (interquartile 
range 1.9-5.3) vs. 3.9 nM/ml*hr for controls (interquartile range 3.0-6.6), (p< 0.01, Figure 
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4a).  While there was a significant decrease in circulating chitinase activity in children with 
asthma (median decrease 0.4 nM/ml*hr, p< 0.01), there was no significant change in 
chitinase activity in the control subjects after surgery (median no change, p=0.83).  Within 
the asthma group, chitinase activity significantly decreased in subjects with improved 
control (p=0.001), while it was unchanged in those who did not improve (p=0.73, Figure 
4b).  Baseline chitinase activity was also significantly higher in subjects whose asthma 
control improved versus those whose control did not, median 3.5 nM/ml*hr (interquartile 
range 2.6-6.6) versus 2.2 nM/ml*hr (interquartile range 1.4-3.5) nM/ml*hr, p< 0.01).  YKL-
40 levels were higher among children with asthma (median 41.5 ng/mL versus 35.5 ng/mL , 
interquartile ranges 27.5-62.4 versus 25.8-50.1), but this was result was not statistically 
significant (Figure 4a).  This trend corresponded to the lower prevalence in the asthmatic 
population of the promoter SNP 131 GC, which increases YKL-40 expression.  YKL-40 
levels not change significantly in either study group over the study period (Figure 4c).  
Improvement in asthma control did not correlate with baseline YKL-40 level, change in 
YKL-40 level over the study period, or baseline IgE levels.   
In the subgroup analysis of children with poorly-controlled asthmatic subjects at 
baseline, the decrease in chitinase activity remained statistically significant when disease 
activity asthma control improved (median decrease 0.9 nM/ml*hr, p< 0.01), but not when 
disease activity control remained unchanged (median no change, p=1.00), as defined by the 
composite variable (Figure 4d).  In this subgroup, baseline chitinase activity was again 
significantly higher in asthmatic subjects whose asthma control improved versus those 
whose asthma control did not (median 3.4 versus 1.9 nM/ml*hr, interquartile ranges 2.4-
5.4 versus 0.8-3.0, p< 0.05).  A baseline chitinase activity ≥ 2.35 predicted improvement 
with 82% sensitivity and 80% specificity among children with poorly-controlled asthma. 
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Gene Expression Analysis 
In nasal epithelial samples, 46 exon clusters including 32 known genes were 
differentially expressed among children with asthma between those with improved control 
and those without(unadjusted p<0.05, |Fold change (FC)|>1.5, Table C).  Using NCBI 
databases, transcripts related to asthma, the upper airway, or the inflammatory response 
were identified.  Serpin Peptidase inhibitor B2 (SerpinB2), previously associated with 
asthma, was down-regulated in the nasal epithelium of children with asthma with improved 
control versus those without improved control (p<0.01, FC -1.96).  It was also down-
regulated in children with improved asthma versus control subjects (p=0.03, FC -1.61).  
Other inflammatory-related genes with differential expression in the nasal epithelium of 
children with improved control versus those without improved control included two 
glutathione S-transferases (GSTM1, p=0.03, FC -2.45; and GSTM4, p<0.01, FC -1.51) and IGF 
binding protein 2 (IGFBP2, p=0.01, FC -1.50), which were down-regulated at baseline among 
children with improved control.  A leukocyte immunoglobulin-like receptor (LILRB4, 
p=0.04, FC 1.5), cytolysis protein perforin 1 (PRF1, p=0.02, FC 1.52), and a GTPase involving 
T-cell survival (GIMAP5, p=0.02, FC 1.66) were up-regulated in baseline nasal epithelium 
among children with improved asthma control.  None of the above, aside from SerpinB2, 
was differentially expressed in children with improved asthma versus control subjects.   
In baseline blood samples, 7 exon clusters including 5 known genes were 
differentially expressed (Table C); these included an interferon induced protein (interferon-
induced protein with tetratricopeptide repeats 1-like protein - IFIT1L, p=0.02, FC -1.51) and 
a carboxypeptidase produced by mast cells (CPA3, p<0.001, FC -1.51) which were both 
down-regulated at baseline among children with improved control.  Interestingly, IFIT1 (not 
IFIT1L) was up-regulated in the blood of children with improved asthma control versus 
control subjects.  In tonsil tissue, 9 differentially expressed clusters and 7 known genes 
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were identified, interestingly all of which are on the Y chromosome; none were 
differentially expressed compared to control subjects (Table C). 
 In matched blood samples using pairwise comparisons (Table D), expression of 
SerpinB2 decreased from baseline to follow-up in children with asthma that improved 
(p<0.01, FC -1.54), but not in children with asthma that did not improve or in control 
patients.  This was the only differentially expressed gene among all children with improved 
asthma; when limited to asthma that was poorly controlled at baseline, 25 exon clusters 
with 15 known genes were differentially expressed.  These included SerpinB2, which 
decreased in expression (p=0.01, FC -1.6), as well as interferon induced protein (IFIT1, 
p=0.02, FC 2.27), HERC5 (p=0.04, FC 2.07), CD274 (p=0.04, FC 1.69), LAMP3 (associated with 
Influenza A, p<0.05, FC 1.6), and an olfactory receptor (OR2W3, p=0.04, FC 1.52) which all 
increased in expression.  None of these significantly changed in expression in either 
children with asthma whose control did not improve or control subjects.  In control 
subjects, 29 known genes showed differential expression pre- and post-operatively, 
including interleukin 1B (IL1B, p=0.03, FC 1.53), cyclooxygenase-2 (PTGS2, the inducible 
form, p=0.03, FC 1.5), adrenomedullin (ADM, p=0.04, FC 1.66), and free fatty acid receptor 2 
(FFAR2 or GPR43, p=0.03, FC 1.64), all of which increased in expression.  Granzyme to 
eliminate transformed and virus-infected cells (GZMH, p=0.04, FC -1.65) and NK cell lectin 
receptor (KLRF1, p=0.03, FC -1.65) both decreased in expression over the study period. 
Gene Ontology analysis of differentially expressed genes between children with 
improved asthma control versus those without improved control demonstrated significance 
(p<0.1) in the baseline nasal epithelium for the classes of pathogenesis (p<0.01), MHC Class 
II protein complex (p<0.01), and membrane parts (p=0.08).  In the baseline blood samples, 
serine-type endopeptidase inhibitor activity (p<0.05) was the only significant class. 
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Discussion 
Though a number of observational studies have demonstrated a positive clinical 
effect of adenotonsillectomy on asthma control, these studies have contained limitations in 
size and study design. (32) No study to our knowledge has examined the effect of 
adenostonsillectomy on markers of airway inflammation; we chose to explore chitinases 
given previous, separate findings liking them to both asthma and adenotonsillectomy. (38, 
40)  In this study, we have demonstrated that asthma control and healthcare utilization 
significantly improve after adenotonsillectomy and that this improvement is associated 
with a decrease in chitinase activity in the circulation that is not evident in children without 
asthma.  Therefore, while this procedure has effects on upper airway inflammation and 
mechanics that contributes to improved asthma control, these results suggest that 
adenotonsillectomy also modulates airway inflammation in asthma. 
This longitudinal, observational study followed children with asthma undergoing 
adenotonsillectomy for standard clinical indications, using both clinical and biological 
characterizations.  We used a past physician diagnosis of asthma as our identification 
criteria, which was supported by the statistically lower %FEV1 in the asthmatic group.  The 
asthmatic group also had statistically more children of Hispanic or Latino heritage; 
however, this did not significantly correlate with chitinase activity or YKL-40 levels. A six 
month follow-up was chosen to minimize any natural changes of asthma control with age, 
but to provide enough time to see clinical and biological changes in airway inflammation.   
The study demonstrated that a vast majority of subjects with asthma undergoing 
adenotonsillectomy reported improvement in symptoms after 6 months.  75% of all 
children with asthma not already maximally controlled at baseline, and therefore with room 
to improve, reported symptom improvement. 85% of children with poorly-controlled 
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asthma at baseline reported improvement.  Response was significantly associated with a 
lower baseline ACT score, indicating that those with poorly-controlled asthma were most 
likely to see a benefit from the surgery, and listing environmental exposures as a trigger 
(including exposures outside the home, weather changes, and pollution). 
ACT score, a validated tool to monitor asthma symptoms and severity, increased on 
average over 3 points from baseline to post-operative follow-up. An initial group of 29 
subjects with asthma enrolled in the study had baseline scores collected after the 
procedure; median baseline ACT score in this group was identical to baseline ACT scores 
collected pre-operatively (score of 22), and thus, all scores were included in analysis. 
A strength of this study is that we have identified a serum biological marker, 
chitinase activity, which decreases with improvement in asthma after adenotonsillectomy 
but does not change in subjects without asthma undergoing the procedure.  Given the 
difficulties of performing a randomized controlled trial of surgery for pediatric asthma 
patients, identifying positive clinical and biological predictors for symptom improvement 
would help to categorize patients most likely to benefit from adenotonsillectomy and 
further justify a biological effect of the surgery on asthmatic inflammation.  Higher serum 
chitinase activity was also significantly associated with improvement in disease activity in 
both the entire cohort of individuals with asthma as well as the subgroup with poorly-
controlled asthma at baseline.  This data suggest that the surgery improves not only clinical 
asthma symptoms, but also has a biological effect on inflammation associated with asthma. 
Genotype analysis of our baseline population showed a higher prevalence of the 
CHIT1 24-bp exon 10 duplication in children with asthma who were undergoing 
adenotonsillectomy.  Correspondingly, baseline chitinase activity was significantly lower in 
this population.  These results are somewhat surprising since chitinase activity also 
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decreased in children whose asthma control improved following the procedure, and 
genotype did not associate with improvement.  One possibility is differences in genetic 
predisposition versus a response to an environmental effect (Figure 5).  Specifically, our 
data suggest that among children with tonsillar disease requiring adenotonsillectomy, 
children with the mutation are more likely to have asthma, due to an inherently decreased 
ability to modulate the effect of environmental substances on the airway (including chitin), 
potentially related to the tonsils.  This may result in more inflammation in the airway and 
the development of asthma.  Because we only explored this in a population of children with 
tonsillar pathology, these conclusions cannot be applied to children with asthma as a whole. 
The decline in chitinase activity following the surgery may represent an 
environmental response rather than an inherent trait.  The results suggest that in patients 
who improve after adenotonsillectomy, tonsillar inflammation and hypertrophy may 
contribute to inflammation of the lower airways.  In accordance with the “one-airway 
hypothesis,” removing the tonsils may reduce inflammation in the lower airway, decrease 
chitinase activity, and improve asthma control.  Those who do not improve control may 
have different triggers or a distinct form of asthma, and thus chitinase levels are likely to 
remain unchanged following the procedure in this group.  Chitotriosidase has been shown 
to have both pro-and anti-inflammatory properties. Whether the enzyme is responding to 
inflammation in the airways induced in the environment as an attempt at negative feedback 
or mediating the inflammation occurring in the airways cannot be discerned by this study.   
While prior studies have demonstrated a strong association between serum YKL-40 
and asthma severity (40), it was another chitinase family protein, chitotriosidase, whose 
activity was found in this study to correlate with asthma and improvement in symptoms 
after surgery.  This distinction may be due to differences in the mechanism of chitin 
response and Th2 inflammation in children and adults.  Additionally, as CHIT1 expression is 
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elevated in hypertrophied adenoid tissue of children with chronic upper airway and sinus 
disease (38), chitotriosidase may play a unique role in airway inflammation triggered by 
hypertrophied adenotonsillar tissue.  A future direction will be to measure chitotriosidase 
activity and YKL-40 levels in adenotonsillar tissue of children with and without asthma. 
To our knowledge, global gene expression has never been studied in patients 
undergoing adenotonsillectomy.  This analysis demonstrated a number of relevant genes 
that may act as biomarkers for changes in asthma control following to adenotonsillectomy.  
The most promising is Serpin Peptidase inhibitor B2 (SerpinB2) since it has been implicated 
in asthma previously, and it was differentially expressed in multiple compartments - blood 
and nasal epithelial tissue.  Interestingly, SerpinB2 was downregulated in the nasal 
epithelium among children whose asthma control improved versus children in which it did 
not, and also decreased in expression in the blood from baseline to follow-up in children 
that improved (but not in controls or children that did not improve).  Serpin peptidase 
inhibitor 2 inhibits tPA and uPA, thus preventing the activation of plasmin and promoting 
fibrin formation.  Its expression is provoked by IL-13. (51)  Fibrinogen and thrombin 
accumulation in the airways has been shown to be involved in airway hyperresponsiveness. 
(61)  SerpinB2 and carboxypeptidase A3, a mast cell product, were previously shown to be 
up-regulated in genome wide profiling of asthmatic bronchial epithelium.  (51) Response to 
corticosteroids was associated with decreased expression of SerpinB2; likewise, in our 
study serum expression of SerpinB2 decreased in children with improved asthma control 
after adenotonsillectomy.  Both higher SerpinB2 levels and carboxypeptidase A3 levels have 
been shown, in separate studies, to predict response to corticosteroids. (62)  However, we 
identified that lower expression of SerpinB2 and carboxypeptidase A3 in the nasal 
epithelium at baseline predicted improvement after surgery.  This pattern may identify a 
subgroup of children with asthma, possibly of a non-allergic type (given low levels of 
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carboxypeptidase A3), unlikely to be controlled by conventional therapies and likely to 
improve by adenotonsillectomy.  Additionally, SerpinB2 knockout mice poorly regulate Th1 
responses. (63)  Thus, children with low baseline SerpinB2 levels may have an underlying 
susceptibility to adenotonsillar-induced airway inflammation. 
Glutathione S-transferases have also been implicated in asthma, and two (GSTM1 
and GSTM4) were found to be down-regulated in the nasal epithelium of children whose 
control improved.  Children null for the GSTM1 allele were more susceptible to asthma 
associated with environmental tobacco smoke; in older children, the GSTM1 null status 
interacted with smoke exposure to reduce peak expiratory flow rate. (64)  Likewise, 
children with asthma undergoing tonsillectomy with low glutathione s-transferase 
expression in the airway may be more susceptible to environmental stress on the airway 
from tonsillar inflammation, and more likely to improve from adenotonsillectomy. 
An interferon induced protein, IFIT1, also increased in expression in matched blood 
samples of children with uncontrolled asthma at baseline that improved control after 
surgery, but not in control subjects or children with uncontrolled asthma that did not 
improve.  This may be relevant since IFIT1L was found to be down-regulated at baseline in 
the blood of children with improved control as well.  IFIT1 is an antiviral protein expressed 
highly after viral infection. (65) 
A number of other inflammatory proteins also changed in expression in the blood in 
control subjects.  This is the first time that changes in gene expression related to 
adenotonsillectomy are reported.  These inflammatory proteins include interleukin-1 β, 
cyclooxygenase-2 (PTGS2, the inducible form), adrenomedullin (ADM), and free fatty acid 
receptor 2 (FFAR2, or Gpr43), all of which increased in expression.  Granzyme-H, which 
eliminates transformed and virus-infected cells, and NK cell lectin receptor (KLRF1) both 
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decreased in expression over the study period.  These changes support the notion that 
adenotonsillectomy affects inflammatory pathways, regardless of asthma status. Of these, 
IL-1β has previously been shown to exist in high concentrations in chronically inflamed 
adenotonsillar tissue in children. (66)  Others have been implicated in airway inflammation. 
COX-2 is implicated in asthma, particular in nasal polyposis and aspirin-associated asthma. 
(67)  Adrenomedullin has been shown to suppress Th-2 related inflammation in mice. (68)  
Mice deficient for Gpr43, a G protein coupled receptor in the gut for short chain fatty acids, 
have hyperractive neutrophilic responses. (69)  Granzyme-H targets adenovirus-infected 
cells by neutralizing an inhibitor of Granzyme B. (70)  KLRF1 has been shown to stimulate 
CD8 T cells with an inflammatory NK-like phenotype. (71) 
Limitations to the observational study include regression to the mean; however 
longitudinal measurement of ACT scores and other measures of asthma control support our 
findings.  Though 29 ‘baseline’ ACT scores were collected during the post-operative follow-
up period due to a change in study design, the median of these scores did not differ from the 
median of scores truly collected at baseline.  While this minimizes the possibility of a recall 
bias due to the timing of the questionnaire, it does not eliminate such a possibility.  Our 
asthmatic group also had a high prevalence of poorly-controlled asthma and was thus more 
severe than population data; however, this may be explained given our starting point of 
children who were candidates for adenotonsillectomy, and thus, may have been more 
connected to the medical system or more likely to have concurrent illnesses. Another 
limitation is the effect of seasonal variability with a 6 month follow-up period; however, this 
was controlled by enrolling participants year round.  Though follow-up was targeted at six 
months, actual mean follow-up time was 7 months, and ranged from 5 to 12 months.  This 
variability may have likewise affected post-operative results.  Additionally, limited PFT data 
in a young population made objective measures of asthma improvement difficult to obtain.   
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Though this study was designed to specifically examine patients undergoing 
adenotonsillectomy, the results suggest further studies comparing changes in asthma 
control and chitinase activity to a non-surgical pediatric asthma population. 
Finally, limitations to the gene expression analysis include heterogeneous cell types 
in all three tissues, inability to perform post hoc correction for multiple comparisons due to 
lack of results, and batch effect due to differences in sample processing including RIN 
number and processing date.  It is also curious that in the baseline tonsil samples, all 
differentially expressed genes were on the Y chromosome, indicating an amplification or 
detection anomaly. 
This study demonstrates that a vast majority of children with asthma, and 
particularly those with poorly-controlled asthma, undergoing adenotonsillectomy for 
standard indications are likely to see an improvement in disease control.  Clinical markers 
associated with response include lower ACT scores at baseline, environmental triggers of 
asthma, and higher serum chitinase activity at baseline.  Additionally, a number of asthma-
related or inflammatory-related genes were found to be differentially expressed between 
children with improved asthma control and children without improved control.  SerpinB2, a 
plasmin activation inhibitor previously shown to be related with asthma, may be of 
particular interest as a marker of change in airway inflammation.  This data suggest that the 
surgery affects asthma control by modulating inflammation, rather than just altering airway 
mechanics.  The clinical, serum chitinase, and expression patterns could identify a subgroup 
of children with poorly-controlled asthma likely to benefit from the surgery, and support 
the rationale behind adenotonsillectomy as an intervention for asthma.  Prospective studies 
of children with asthma will be required to determine the clinical and biologic phenotype of 
those most likely to have clinical improvement of asthma control from surgery.  
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Figure 1 
 
Study design and follow-up rates for Asthma and Control cohorts undergoing 
adenotonsillectomy 
 
  
130 pediatric patients 
(ages 2-18) undergoing 
adenotonsillectomy enrolled
66 Asthmatics
62 (94%) with initial 
bloodwork
58 subjects 
achieved follow-up 
(88%)
42 subjects 
completed follow-
up bloodwork
(72%)
64 Controls
60 (94%) with initial 
bloodwork
47 subjects 
achieved follow-up 
(73%)
25 subjects 
completed follow-
up bloodwork
(53%)
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Figure 2 
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Asthma Control Test (ACT) scores at baseline and follow-up 
Median score displayed with interquartile ranges, error bars represent range of minimum and 
maximum scores.  p-values calculated by Wilcoxon Signed Rank Test. 
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Figure 3 
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Chitotriosidase (CHIT1) and YKL-40 (CHI3L1) Genotypes in Asthma and Control 
cohorts 
p-values calculated by t-test. 
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Figure 4 
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a s th m a
Chitinase Activity and YKL-40 Level in Asthma and Control cohorts 
a. p-values calculated by Mann Whitney U Test.  b-c. p-values calculated by Wilcoxon Signed Rank 
Test.  d. Poorly-controlled defined as baseline Asthma Control Test (ACT) Score < 20, rescue SABA 
usage > 2 times/week, Emergency Room / Urgent Care Visits ≥ 2/year, or Oral Corticosteroid (OCS) 
courses ≥ 2/year. p-values calculated by Wilcoxon Signed Rank Test.  Baseline  chitinase activity of 
the improved group was also significantly higher than the not-improved group, p<0.05 by Mann 
Whitney U Test. 
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Figure 5 
a. 
 
b. 
 
Concept: Adenotonsillectomy, Chitinases, and Asthma Control 
a. CHIT1 polymorphism affects asthma prevalence in patients undergoing adenotonsillectomy 
The genotypic data suggests that the CHIT1 polymorphism, which results in lower 
chitotriosidase activity, correlates with asthma prevalence among patients undergoing 
adenotonsillectomy.  Chitinases may modulate the effect of environmental stressors 
(including chitin) on airway inflammation, thus lowering asthma prevalence.  Those with the 
mutant CHIT1 allele have lower chitinase activity, and may be unable to modulate this 
inflammation, possibly relating to upper airway disease including adenotonsillar 
hypertrophy and inflammation, raising asthma prevalence.   
b. Tonsillectomy induces changes in systemic inflammation associated with asthma 
Meanwhile, longitudinal results suggest that patients with higher chitinase levels at baseline 
with tonsillar hypertrophy/inflammation & asthma are more likely to see improvement after 
tonsillectomy.  This may be a reflection of both the airway-specific and systemic 
inflammatory response to tonsillar hypertrophy and inflammation, and thus chitinase levels 
decline after adenotonsillectomy correlating with a decrease in asthma severity. 
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Table A 
Baseline demographics and clinical characteristics of Asthma and Control cohorts 
    Asthmatics (n=66)  Controls (n=64)  p-value  
Age - Mean (Range) 6.4 (2-17) 5.8 (2-18) 0.17* 
Females – n (%) 
Males – n (%)  
25 (38) 
41 (62)  
33 (52) 
31 (48)  
0.16
‡
  
Race – n (%) White/Caucasian 
  Black/African American 
  Other 
 
Hispanic and/or Latino Ethnicity – n (%) 
54 (82)  
11 (17)  
1 (1)  
 
32 (49)  
43 (67)  
20 (31)  
1 (2)  
  
19 (30)  
0.13
‡‡
 
  
  
  
0.03
‡
 
Comorbidities  Atopy – n (%) 
  History of GERD – n (%) 
  Sinusitis – n (%) 
49 (77)  
25 (38)  
22 (33)  
32 (51)  
9 (14)  
12 (19)  
<0.01
‡
  
<0.01
‡
  
0.11
‡
 
Second Hand Smoke Exposure – n (%) 18 (29)  17 (27)  1.00
‡
  
Weight (Described) – n (%)  
  Normal or Underweight 
  Overweight/Obese  
 
47 (71)  
19 (29)  
 
51 (80)  
13 (20)  
0.31
‡
 
Residence  Urban – n (%) 
  Suburban – n (%) 
  Rural – n (%) 
24 (37)  
34 (52)  
7 (11)  
20 (31)  
38 (60)  
6 (9)  
0.72
‡‡
 
Tonsillectomy Indication – n (%)  
  Hypertrophy, including OSA 
  Chronic/Recurrent Infection 
  
46 (70)  
18 (27)  
  
52 (81)  
12 (19)  
0.30
‡
  
  
FEV1 % Predicted – Median  93  112% 0.03* 
IgE Levels (IU/mL) – Median  45.7  25.4  0.23* 
* Mann-Whitney U Test; ‡Fisher’s Exact Test ; ‡‡Chi-Squared Test  
  Levin et. al, 48   
 
Table B 
Change of clinical characteristics from baseline to follow-up in Asthma cohort (n=58) 
Event frequency per 12 months Baseline (mean) Follow-up (mean) Wilcoxon Signed 
Rank Test 
Emergency Room / Urgent Care Visits for Asthma  1.88 0.40 0.01  
Oral corticosteroid courses  1.11 0.21 <0.01  
Hospitalizations for Asthma  0.09 0.00 0.06  
Missed School Days due to Asthma  3.86 2.00 0.01  
Total Missed Parental Work Days  2.79 1.13 0.03  
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Table C 
Differentially expressed transcripts at baseline between children with asthma with 
improved control versus those without improved control 
Nasal Epithelium 
p-value Fold Change Gene Description 
0.014 2.57 HLA-DQB1| 
HLA-DRB1| 
HLA-DQB2| 
HLA-DRB2| 
HLA-DRB3| 
HLA-DRB4| 
HLA-DRB5| 
ZNF749| 
RNASE2| 
hCG_1998957 
major histocompatibility complex, class II, DQ beta 1 |  
major histocompatibility complex, class II, DR beta 1 | 
major histocompatibility complex, class II, DQ beta 2 |  
major histocompatibility complex, class II, DR beta 2 |  
major histocompatibility complex, class II, DR beta 3 |  
major histocompatibility complex, class II, DR beta 4 |  
major histocompatibility complex, class II, DR beta 5 |  
zinc finger protein 749 |  
ribonuclease, RNase A family, 2 (liver, eosinophil-derived 
neurotoxin) | similar to hCG199264 
0.030 -2.45 GSTM1 glutathione S-transferase M1 
0.003 2.44 HLA-DRB5| 
HLA-DQB1| 
HLA-DQB2| 
HLA-DRB1| 
HLA-DRB2| 
HLA-DRB3| 
HLA-DRB4| 
ZNF749| 
RNASE2| 
hCG_1998957 
major histocompatibility complex, class II, DR beta 5 |  
major histocompatibility complex, class II, DQ beta 1 |  
major histocompatibility complex, class II, DQ beta 2 |  
major histocompatibility complex, class II, DR beta 1 |  
major histocompatibility complex, class II, DR beta 2 |  
major histocompatibility complex, class II, DR beta 3 |  
major histocompatibility complex, class II, DR beta 4 |  
zinc finger protein 749 |  
ribonuclease, RNase A family, 2 (liver, eosinophil-derived 
neurotoxin) | similar to hCG199264 
0.012 -2.10 FLJ21511  
0.009 -1.96 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 
0.047 -1.96 CD177  
0.002 1.93 ND6 NADH dehydrogenase, subunit 6 (complex I) 
0.014 -1.91 SLC22A16 solute carrier family 22 (organic cation/carnitine transporter), 
member 16 
0.043 -1.82 NELL2 NEL-like 2 (chicken) 
0.034 1.80 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
0.003 -1.78 ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
0.012 1.77 ADAMDEC1 ADAM-like, decysin 1 
0.018 1.76 KIR2DL3| 
KIR2DS2| 
KIR2DS4| 
KIR2DL2| 
KIR2DS1| 
KIR2DL1| 
KIR3DL2 
killer cell immunoglobulin-like receptor 
0.016 -1.74 CLDN3 claudin 3 
0.010 -1.73 CYP2S1 cytochrome P450, family 2, subfamily S, polypeptide 1 
0.005 -1.72 AHNAK2 AHNAK nucleoprotein 2 
0.037 -1.68 VSNL1 visinin-like 1 
0.044 1.67 SORD sorbitol dehydrogenase 
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0.021 1.66 GIMAP5 GTPase, IMAP family member 5 
0.015 -1.62 ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide 
0.014 -1.60 PTPRT protein tyrosine phosphatase, receptor type, T 
0.040 1.60 SIGLEC10 sialic acid binding Ig-like lectin 10 
0.009 -1.58 CLDN16 claudin 16 
0.009 -1.56 LAMC2 laminin, gamma 2 
0.029 -1.55 CKB creatine kinase, brain 
0.003 -1.54 KCND3 potassium voltage-gated channel, Shal-related subfamily, 
member 3 
0.026 1.52 PRF1 perforin 1 (pore forming protein) 
0.017 -1.52 CDH13 cadherin 13, H-cadherin (heart) 
0.003 -1.51 GSTM4| 
GSTM2 
glutathione S-transferase M4 |  
glutathione S-transferase M2 (muscle) 
0.010 -1.50 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
0.031 -1.50 DENND2C DENN/MADD domain containing 2C 
0.043 1.50 LILRB4 leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 4 
 
Blood 
p-value Fold Change Gene Description 
0.001 -1.62 XRRA1 X-ray radiation resistance associated 1 
0.001 -1.61 OVOS ovostatin 
0.001 -1.60 OVOS2 ovostatin 2 
0.023 -1.51 IFIT1L interferon-induced protein with tetratricopeptide repeats 1-like 
0.0004 -1.51 CPA3 carboxypeptidase A3 (mast cell) 
 
Tonsil 
p-value Fold Change Gene Description 
0.031 -3.39 UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked 
0.035 -3.05 RPS4Y1 ribosomal protein S4, Y-linked 1 
0.019 -2.80 JARID1D jumonji, AT rich interactive domain 1D 
0.030 -2.79 EIF1AY eukaryotic translation initiation factor 1A, Y-linked 
0.029 -2.79 DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
0.027 -2.66 USP9Y ubiquitin specific peptidase 9, Y-linked (fat facets-like, 
Drosophila) 
0.025 -1.85 ZFY zinc finger protein, Y-linked 
Differentially expressed genes determined by non-corrected p-value <0.05, |Fold change|>1.5. 
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Table D 
Differentially expressed transcripts at follow-up versus baseline in matched blood 
samples 
Improved Asthma Control 
p-value Fold Change Gene Description 
0.009 -1.54 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 
 
Non-Improved Asthma Control 
p-value Fold Change Gene Description 
0.029 1.52 SNHG10| 
SCARNA13 
small nucleolar RNA host gene (non-protein coding) 10 |  
small Cajal body-specific RNA 13 
 
Improved Asthma Control Among Children with poorly controlled asthma 
p-value Fold Change Gene Description 
0.012 2.59 RSAD2 radical S-adenosyl methionine domain containing 2 
0.022 2.27 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 
0.039 2.07 HERC5 hect domain and RLD 5 
0.024 1.73 EPSTI1 epithelial stromal interaction 1 (breast) 
0.040 1.69 CD274  
0.004 1.65 XK X-linked Kx blood group (McLeod syndrome) 
0.024 1.62 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 
0.011 -1.60 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 
0.048 1.60 LAMP3 lysosomal-associated membrane protein 3 
0.006 1.58 DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 
0.040 1.55 ELOVL7 ELOVL family member 7, elongation of long chain fatty acids 
(yeast) 
0.037 1.52 OR2W3 olfactory receptor, family 2, subfamily W, member 3 
0.040 -1.51 SH2D2A SH2 domain protein 2A 
0.038 1.51 FECH ferrochelatase (protoporphyria) 
0.013 1.51 TSPAN7 tetraspanin 7 
 
Control Subjects 
p-value Fold Change Gene Description 
0.042 1.77 KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 
0.011 1.75 GPR109A G protein-coupled receptor 109A 
0.014 1.74 GPR109B G protein-coupled receptor 109B 
0.023 1.70 ACSL1 acyl-CoA synthetase long-chain family member 1 
0.009 1.69 PROK2 prokineticin 2 
0.041 1.68 GK|GK3P glycerol kinase | glycerol kinase 3 pseudogene 
0.013 1.67 MGAM maltase-glucoamylase (alpha-glucosidase) 
0.040 1.66 ADM adrenomedullin 
0.042 -1.65 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) 
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0.027 -1.65 KLRF1 killer cell lectin-like receptor subfamily F, member 1 
0.029 1.64 FFAR2 free fatty acid receptor 2 
0.005 1.63 ROPN1L ropporin 1-like 
0.007 1.63 VNN3 vanin 3 
0.032 1.58 GPR97 G protein-coupled receptor 97 
0.046 1.58 UNQ9368 RTFV9368 
0.030 1.53 IL1B interleukin 1, beta 
0.013 1.52 STEAP4 STEAP family member 4 
0.036 1.51 KREMEN1 kringle containing transmembrane protein 1 
0.031 1.50 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
Differentially expressed genes determined by non-corrected p-value <0.05, |Fold change|>1.5. 
